Form 13-F position report

THERIVA BIOLOGICS INC

Reported by MORGAN STANLEY

TOVX CUSIP 87164U409 Manager CIK 0000895421

Reported 0 shares, down 15 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 9 Through Q3 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-09-30 0
2022-12-31 305
2023-03-31 7
2023-06-30 12
2023-09-30 5
2023-12-31 222
2024-03-31 7
2024-06-30 4
2024-09-30 27876
2024-09-30 0
2024-12-31 0
2025-12-31 42080
2026-03-31 4621
2026-06-30 5079
2026-09-30 4567

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for THERIVA BIOLOGICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 20,299 0 (0.0%) < 0.01% $4,567 2026-11-13
Q2 2026 Reduced 20,299 -3,303 (-14.0%) < 0.01% $5,079 2026-08-13
Q1 2026 Reduced 23,602 -176,398 (-88.2%) < 0.01% $4,621 2026-05-15
Q4 2025 New 200,000 +200,000 (0.0%) < 0.01% $42,080 2026-02-13
Q4 2024 Reduced 0 -20,200 (-100.0%) 0 $0 2025-02-14
Q3 2024 Reduced 0 -15 (-100.0%) 0 $0 2024-11-14
Q3 2024 New 20,200 +20,200 (0.0%) < 0.01% $27,876 2024-11-14
Q2 2024 Unchanged 15 0 (0.0%) < 0.01% $4 2024-08-14
Q1 2024 Reduced 15 -500 (-97.1%) < 0.01% $7 2024-05-15
Q4 2023 Added 515 +505 (5050.0%) < 0.01% $222 2024-02-13
Q3 2023 Reduced 10 -2 (-16.7%) < 0.01% $5 2023-11-15
Q2 2023 Added 12 +2 (20.0%) < 0.01% $12 2023-08-14
Q1 2023 Reduced 10 -661 (-98.5%) < 0.01% $7 2023-05-15
Q4 2022 Added 671 +373 (125.2%) < 0.01% $305 2023-02-14
Q3 2022 New 298 +298 (0.0%) 0 $0 2022-11-14

Who else reported the position

21 managers reported THERIVA BIOLOGICS INC for Q3 2024.

Managers reporting THERIVA BIOLOGICS INC in Q3 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
IFP Advisors Inc Added 296 +284 < 0.01% $43 8 qtrs
FMR LLC Reduced 0 -500 0 $0 5 qtrs
Bank of America Corporation Reduced 0 -146 0 $0 9 qtrs
Tower Research Capital LLC TRC Reduced 0 -145 0 $0 9 qtrs
WELLS FARGO & COMPANY MN Reduced 0 -100 0 $0 9 qtrs
Planning Capital Management Corp Reduced 0 -110 0 $0 2 qtrs
TWO SIGMA SECURITIES LLC Reduced 0 -61,023 0 $0 5 qtrs
CONCOURSE FINANCIAL GROUP SECURITIES INC Unchanged 0 0 0 $0 9 qtrs
MSD Partners L P Reduced 0 -598,411 0 $0 2 qtrs
BLAIR WILLIAM & CO IL Reduced 0 -10,153 0 $0 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2024
Filed
November 14, 2024
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.